Company intelligence / Profile preview

KYE Pharmaceuticals Inc.

Mississauga/Toronto, Ontario, Canadakyepharma.com ↗

Ownership: Private
Development stage: Commercial

Overview

KYE Pharmaceuticals is a commercial-stage biopharmaceutical company that identifies, licenses, and commercializes novel medicines for the Canadian market. Recent approvals include QUILLIVANT® ER for ADHD and ACCRUFeR® for iron deficiency anemia. The company has also secured exclusive Canadian rights to commercialize AGAMREE® for Duchenne Muscular Dystrophy.

Therapeutic areas: Rare DiseasesHematologyOtherPsychiatryCardiovascularNeurology
Modalities: Small moleculesoral suspensionschewable tablets
Industry: Biotech

Drug pipeline

4 assets

QUILLIVANT ER

Commercial

Indications: ADHD

3 more assets in the full pipeline.

Request access →

Partnerships

Catalyst PharmaceuticalsTris PharmaShield Therapeutics

Beyond the preview

Go deeper on KYE Pharmaceuticals Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KYE Pharmaceuticals Inc..

Explore the full profile